Genetische Diagnostik und molekulare Ansätze bei pulmonalarterieller Hypertonie

Zusammenfassung

Die kürzlich erschienenen, neuen Leitlinien für pulmonale Hypertonie bieten den bisher ausführlichsten Einblick in die genetische Diagnostik und Beratung von PAH-Patient*innen. Aber auch der Stellenwert des klinischen Screenings von gesunden Anlageträger*innen wird hervorgehoben sowie der genetischen Testung bei Patient*innen mit dem Verdacht auf eine pulmonal veno-okklusive Erkrankung. Die jeweiligen Abschnitte der Leitlinien werden im Folgenden in die aktuelle Datenlage eingebettet und kommentiert. Abschließend geben wir einen Ausblick auf neue molekulare Ansätze von Sotatercept über Ionenkanäle bis hin zu neuen therapeutischen Ansatzpunkten.

Abstract

The recently published new European guidelines for diagnosis and treatment of pulmonary hypertension now offer the so far most extensive description of genetic testing and counselling for pulmonary arterial hypertension patients. In addition, the importance of a clinical screening of healthy mutation carriers is highlighted as well as the genetic testing of patients with a suspicion of pulmonary veno-occlusive disease. We frame the respective parts of the guidelines on genetic testing and counselling in the context of recent data and provide comments. Finally, we give an outlook on novel molecular approaches starting from Sotatercept, addressing ion channels and novel therapeutic developments.

Schlüsselwörter

Genetik - pulmonalarterielle Hypertonie - molekular genetische Diagnostik - genetische Beratung

Keywords

genetics - pulmonary arterial hypertension - molecular genetic diagnostics - genetic counselling

Publication History

Article published online:
14 November 2023

• Literatur

• 1 Rich S. World Symposium – Pirmary Pulmonary Hypertension 1998. World Health Organziation; 1998
• 2 Deng Z, Morse JH, Slager SL. et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744
• 3 Grünig E, Janssen B, Mereles D. et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000; 102: 1145-1150
• 4 Thomson JR, Machado RD, Pauciulo MW. et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-745
• 5 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879
• 6 Hoeper MM, Badesch DB, Ghofrani HA. et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023;
• 7 Bundesministerium der Justiz. Gendiagnostikgesetz. 2009 (BGBl. I S. 2529; 3672), das zuletzt durch Artikel 15 Absatz 4 des Gesetzes 04.5.2021 (BGBl. I S. 882) geändert worden ist.
• 8 Deutsche Gesellschaft für Humangenetik e.V. (GfH), Berufsverband Deutscher Humangenetiker e. V. (BVDH). S2k-Leitlinie Humangenetische Diagnostik und Genetische Beratung. Medizinische Genetik 2018; 30: 469-522
• 9 Song J, Eichstaedt CA, Rodríguez Viales R. et al. Identification of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. Clinical science (London, England: 1979) 2016; 130: 2043-2052
• 10 Eichstaedt CA, Song J, Benjamin N. et al. EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension. Respir Res 2016; 17: 141
• 11 Galiè N, Hoeper MM, Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537
• 12 Galiè N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975
• 13 Welch CL, Aldred MA, Balachandar S. et al. Defining the Clinical Validity of Genes Reported to Cause Pulmonary Arterial Hypertension. Genet Med 2023; 25: 100925
• 14 Eyries M, Montani D, Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46: 65-69
• 15 Hadinnapola C, Bleda M, Haimel M. et al. Phenotypic Characterisation of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically with Pulmonary Arterial Hypertension. Circulation 2017; 136: 2022-2033
• 16 Larkin EK, Newman JH, Austin ED. et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 892-896
• 17 Eichstaedt CA, Belge C, Chung WK. et al. Genetic counselling and testing in pulmonary arterial hypertension – A consensus statement on behalf of the International Consortium for Genetic Studies in PAH. Eur Respir J 2023; 61: 2201471
• 18 Montani D, Girerd B, Jais X. et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J 2021; 58: 2004229
• 19 Grünig E, Weissmann S, Ehlken N. et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009; 119: 1747-1757
• 20 El-Yafawi R, Rancourt D, Hacobian M. et al. Pulmonary hypertension subjects exhibit right ventricular transient exertional dilation during supine exercise stress echocardiography. Pulm Circ 2019; 9: 2045894019851904
• 21 Harbaum L, Rhodes CJ, Wharton J. et al. Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2022; 205: 1449-1460
• 22 Southgate L, Machado RD, Gräf S. et al. Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol 2020; 17: 85-95
• 23 Swietlik EM, Greene D, Zhu N. et al. Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. Circ Genom Precis Med 2021; 14: e003155
• 24 Machado R, Welch CL, Haimel M. et al. Biallelic variants of ATP13A3 cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality. J Med Genet 2021;
• 25 Humbert M, McLaughlin V, Gibbs JSR. et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384: 1204-1215
• 26 Lane KB, Machado RD, Pauciulo MW. et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-84
• 27 Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol 1994; 144: 286-295
• 28 Du L, Sullivan CC, Chu D. et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348: 500-509
• 29 Yung LM, Yang P, Joshi S. et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 2020; 12
• 30 Hoeper MM, Barst RJ, Bourge RC. et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-1138
• 31 Xanthouli P, Eichstaedt CA, Fischer C. et al. Pulmonalarterielle Hypertonie bei Frauen. [Pulmonary arterial hypertension in women]. Aktuelle Kardiologie 2021; 11: 30-34
• 32 Tofovic SP, Jackson EK. Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension. Int J Mol Sci 2019; 21
• 33 Kawut SM, Archer-Chicko CL, DeMichele A. et al. Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med 2017; 195: 360-368
• 34 Meloche J, Potus F, Vaillancourt M. et al. Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension. Circ Res 2015; 117: 525-535
• 35 Chelladurai P, Kuenne C, Bourgeois A. et al. Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Sci Transl Med 2022; 14: eabe5407
• 36 Sommer N, Ghofrani HA, Pak O. et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol 2021; 178: 6-30
• 37 Paulin R, Dromparis P, Sutendra G. et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab 2014; 20: 827-839
• 38 Lewis GD, Farrell L, Wood MJ. et al. Metabolic signatures of exercise in human plasma. Sci Transl Med 2010; 2: 33ra37
• 39 Lewis GD, Ngo D, Hemnes AR. et al. Metabolic Profiling of Right Ventricular-Pulmonary Vascular Function Reveals Circulating Biomarkers of Pulmonary Hypertension. J Am Coll Cardiol 2016; 67: 174-189
• 40 Rhodes CJ, Wharton J, Swietlik EM. et al. Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2022;
• 41 Ma L, Roman-Campos D, Austin ED. et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013; 369: 351-361
• 42 Bohnen MS, Ma L, Zhu N. et al. Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circ Genom Precis Med 2018; 11: e002087
• 43 Nagaraj C, Tang B, Balint Z. et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95
• 44 Olschewski A, Li Y, Tang B. et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006; 98: 1072-1080